Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Neurocrine Biosciences Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.95, while Neurocrine Biosciences Inc trades at $176.37 (market cap $17.18B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNK | NBIX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $98.19 | $180.55 |
52-Week Low | $94.66 | $123.10 |
Market Cap | — | $17.18B |
Enterprise Value | — | $16.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $96.00, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though oscillators remain neutral. Recent news highlights strong bond ETF inflows amid Federal Reserve uncertainty and inflation concerns, while the fund's 0.40% expense ratio draws criticism for long-term costs.
The outlook for JNK is cautious due to potential Fed rate hikes and elevated inflation, which may pressure high-yield bonds. While the fund offers attractive dividends, investors face risks from interest rate sensitivity and economic volatility. Analyst sentiment is mixed, with some advocating for yield-seeking strategies but others warning of exhausted tailwinds.
Neurocrine Biosciences (NBIX) trades at $173.63, up 1.61% with strong technical and fundamental momentum. The stock shows bullish moving averages and recent earnings beats, with Q1 2026 EPS of $1.94 exceeding expectations by 59%. Revenue growth accelerated to 44% year-over-year in Q1 2026, reaching $811 million, while net income margin improved to 21.55%. Positive analyst sentiment is driven by Ingrezza's blockbuster performance and pipeline advancements.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus target offering 13% upside. Key opportunities include sustained prescription growth for Ingrezza and Crenessity, plus recent Vykat acquisition synergies. Risks involve pipeline execution, competitive pressures in neuroscience, and dependence on key drug performance. The stock presents a growth opportunity with solid fundamentals but requires monitoring of clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
